Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1623 1629
This examiner grants 48% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18201882 | MULTIBIOTIC AGENTS AND METHODS OF USING THE SAME | Non-Final OA | Flagship Pioneering Innovations V, Inc. |
| 18383256 | AGENTS AND METHODS FOR PREVENTING AND TREATING SKELETAL MUSCLE DISEASES | Non-Final OA | The Regents Of the University of California |
| 18567952 | PESTICIDALLY ACTIVE DIAZINE-AMIDE COMPOUNDS | Non-Final OA | SYNGENTA CROP PROTECTION AG |
| 18058429 | MIXED FATTY ACID SOAP/FATTY ACID BASED INSECTICIDAL, CLEANING, AND ANTIMICROBIAL COMPOSITIONS | Final Rejection | ECOLAB USA INC. |
| 18113981 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISORDERS | Non-Final OA | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK |
| 18237705 | COMPOSITIONS AND METHODS FOR IMPROVED TREATMENT OF PLATINUM-BASED CHEMOTHERAPEUTIC RESISTANT TUMORS | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE |
| 18002433 | DIMETHYL SULFONE FOR TREATMENT OF CHRONICALLY HEAT STRESSED POULTRY | Final Rejection | Evonik Operations GmbH |
| 18291083 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | Non-Final OA | NOVARTIS AG |
| 18480409 | CDK4/6 INHIBITORS AS A TREATMENT FOR CLONAL HEMATOPOIESIS | Non-Final OA | Washington University |
| 17757609 | METHODS FOR INHIBITION OF ALPHA-SYNUCLEIN mRNA USING SMALL MOLECULES | Final Rejection | Rutgers, The State University of New Jersey |
| 15516444 | ATROPINE SULFATE RAPIDLY-DISINTEGRATING SUBLINGUAL TABLETS AND METHODS FOR USE THEREOF FOR TREATMENT OF ACUTE ORGANOPHOSPHATE TOXICITY | Final Rejection | University of Sharjah |
| 17936179 | 23-O-ACETYLALISOL B AS A NOVEL THERAPEUTIC AGENT FOR CORONAVIRUS INDUCED SEVERE ACUTE RESPIRATORY SYNDROME | Final Rejection | The University of Hong Kong |
| 17869346 | INDOMETHACIN PHARMACEUTICAL COMPOSITION | Non-Final OA | FULTON MEDICINALI S.P.A. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy